TVTX: FILSPARI targets $3B annual sales by 2033 as kidney launches expand and pipeline advances
Travere Therapeutics (TVTX) reported strong Q3 results for FILSPARI, with 1,932 patient start forms and $200M in net revenue, demonstrating early penetration in IgAN and FSGS. The company aims for $3B in annual sales for FILSPARI by 2033, supported by expanding kidney disease opportunities, extended patents, and pipeline advancements. This information is based on their Jefferies Global Healthcare Conference Audio Transcript from November 17, 2026.
Bank of America amends its Travere Therapeutics (TVTX) stake report on behalf of five subsidiaries.
Bank of America Corporation has filed an amended beneficial-ownership report for Travere Therapeutics, Inc. (TVTX), disclosing beneficial ownership of 6,810,705 shares, or 7.1% of the company, as of September 30, 2026. The report was filed on behalf of Bank of America and five of its wholly-owned subsidiaries, detailing shared voting power over 6,379,726 shares and shared dispositive power over 6,697,284 shares. The ownership percentage was calculated based on 95,673,465 shares outstanding.
TVTX: FILSPARI growth supports a $3B 2033 goal as two pipeline programs advance
Travere Therapeutics (TVTX) is targeting $3 billion in net product sales by 2033, driven by the strong growth of FILSPARI, which saw a 120% year-over-year sales increase in Q3. The company is also advancing two pipeline programs: pegtibatinase, with Phase III data expected in H2 2027, and civorebrutinib, moving towards late-stage development. This outlook is based on insights from the UBS Global Biopharma Conference 2026.
Weekly Recap: FILSPARI $200M Q3 revenue and 2027 data, 2026 IND plans
Travere Therapeutics, Inc. (TVTX) reported FILSPARI generated $200 million in net revenue in the third quarter, showing strong uptake in FSGS and IgAN. The company anticipates pivotal data for pegtibatinase in the second half of 2027 and plans to submit an Investigational New Drug (IND) application for civorebrutinib by the end of 2026. This recap highlights the financial performance of FILSPARI and key pipeline milestones for Travere Therapeutics.
Form 144 TRAVERE THERAPEUTICS For: 15 November By Investing.com
Investing.com reports on a Form 144 filing for Travere Therapeutics (TVTX) on November 15, 2026. This filing typically indicates an insider's intent to sell restricted or controlled securities. The article provides minimal detail beyond the announcement and includes a snapshot of market data and related news.
(TVTX) Volatility Zones as Tactical Triggers
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) through volatility zones and tactical triggers, providing three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It identifies strong near-term positive sentiment, a mid-term neutral outlook, and a long-term positive bias, alongside specific support and resistance levels for various time horizons. The report highlights elevated downside risk due to a lack of long-term support signals.
Travere Therapeutics grants 65,520 shares in inducement RSUs | TVTX Stock News
Travere Therapeutics, Inc. announced that its Board's Compensation Committee granted inducement equity awards to 20 new employees on November 10, 2026. These grants consist of restricted stock units (RSUs) covering 65,520 shares of common stock, which will vest over four years, with 25% vesting annually, contingent on continued employment. The grants were made as an inducement for the new employees to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
Learn Why The Bull Case For Travere Therapeutics (TVTX) Could Change Following Wider Q3 Loss
Travere Therapeutics (TVTX) reported a wider net loss in Q3 2026 despite higher revenue, driven by increased operating and R&D spending. The company's investment narrative relies on FILSPARI as a commercial anchor and future contributions from pegtibatinase and civorebrutinib to achieve profitability. Analysts anticipate significant revenue growth and a swing to profitability by 2029, though the recent quarter highlights execution risks related to costs and program delivery.
TVTX: FILSPARI momentum continued as pipeline milestones advanced toward 2027
Travere Therapeutics (TVTX) reported strong Q3 net revenue of $200 million for FILSPARI, driven by broad FSGS uptake and continued IgAN prescribing momentum. The company is advancing its pipeline, with pivotal data for peqtibatinase expected in the second half of next year and an IND filing for civorebrutinib planned by year-end. This information is based on their 3rd Annual Guggenheim Healthcare Innovation Conference Audio Transcript from November 10, 2026.
Travere Therapeutics (TVTX) Returned To Losses In Q3, Is A 31% Discount Warranted?
Travere Therapeutics (TVTX) reported Q3 revenue of US$224.56 million, but swung to a net loss of US$52.34 million. Despite recent share price declines, the company has strong long-term momentum and is currently trading 31% below analyst consensus fair value of $75.14. The undervaluation is based on the potential of its drug FILSPARI's growing sales, extended patent protection, and upcoming pipeline advancements, although high R&D and licensing costs remain a risk.
Weekly Recap: Buy consensus, target falls and FILSPARI cuts four markers
Travere Therapeutics (NASDAQ:TVTX) released Phase 3 PROTECT data showing FILSPARI significantly reduced four inflammation and immune-activation biomarkers compared to irbesartan. Analysts maintain a Buy consensus for TVTX, though the average 12-month target has slightly decreased. The company is also planning an IND filing for civorebrutinib, expecting pegtibatinase trial results in 2027, and starting a Phase 4 SPARLIGHT trial.
JP Morgan maintains Travere Therapeutics at Overweight, lowers price target to $86 from $90
JP Morgan has reiterated its "Overweight" rating for Travere Therapeutics but adjusted its price target down to $86 from $90, representing a 4.4% decrease. Despite the reduction, the new price target still suggests a substantial upside of 73.4% from the stock's closing price of $49.60 on November 6. Other recent analyst actions on Travere Therapeutics include "Outperform" and "Buy" ratings with price targets ranging from $67 to $78.
Travere Therapeutics, Inc. (TVTX) Seasonal Returns Chart - Yahoo Finance
This Yahoo Finance article presents the seasonal returns chart for Travere Therapeutics, Inc. (TVTX), showing average monthly price returns from 2016 to 2026. The stock's current price and after-hours trading information are also displayed, indicating a slight increase at market close followed by a decline in after-hours trading.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP) and Travere Therapeutics (TVTX)
This article details conflicting analyst sentiments for three healthcare companies: Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP), and Travere Therapeutics (TVTX). Stifel Nicolaus analysts reiterated a Buy rating for Jazz Pharmaceuticals and Inspire Medical Systems, while maintaining a Hold rating for Travere Therapeutics. The article provides individual analyst ratings, price targets, and overall Street consensus for each company.
Why Travere Therapeutics Stock Is Up 6.1% And What's Next
Travere Therapeutics reported strong third-quarter 2026 revenue of US$224.56 million and record FILSPARI sales, despite a net loss of US$52.34 million. New PROTECT Phase 3 biomarker data for FILSPARI reinforces its importance in rare kidney disease, impacting the company's investment narrative. The article highlights the ongoing need for operational execution and market access for FILSPARI as the company scales its rare kidney and metabolic franchise.
Travere Therapeutics to Participate at Upcoming November 2026 Investor Conferences
Travere Therapeutics (Nasdaq: TVTX) announced its management will participate in four investor conferences in November 2026: the Guggenheim Global Healthcare Conference, Stifel 2026 Healthcare Conference, UBS Global Biopharma Conference, and Jefferies London Healthcare Conference. Live webcasts of the presentations will be available on the Investor page of Travere's website, with replays accessible for 30 days post-event. The company focuses on identifying, developing, and delivering life-changing therapies for rare diseases.
Four November talks from Travere will be webcast, with replays available for up to 30 days.
Travere Therapeutics (Nasdaq: TVTX) announced its management will participate in four investor conferences in November 2026, starting with the Guggenheim Global Healthcare Conference on November 10. Other conferences include the Stifel 2026 Healthcare Conference, UBS Global Biopharma Conference, and Jefferies London Healthcare Conference. Live webcasts and replays for up to 30 days will be available on the company's investor relations website.
Travere Therapeutics Q3 Swings to Loss, Revenue Rises
Travere Therapeutics reported a swing to a net loss in the third quarter of $66.4 million, or $0.99 per share, compared to a net income of $26.8 million, or $0.39 per share, in the prior year. Despite the loss, the company saw a significant increase in total revenue, which rose 127% to $96.8 million, primarily driven by sales of FILSPARI. FILSPARI's net product sales reached $76.2 million for the quarter.
Travere Therapeutics Reports Third Quarter 2026 Financial Results
Travere Therapeutics reported strong financial results for the third quarter of 2026, with U.S. net product sales of FILSPARI reaching $200.2 million, a 120% year-over-year increase. The company is advancing its pipeline with pegtibatinase in Phase 3 for classical homocystinuria and civorebrutinib for immune-mediated kidney diseases, with a U.S. IND submission planned by year-end. Eric Dube also announced his transition of the CEO role to Bradley Campbell in December.
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics (TVTX) reported strong third-quarter results driven by record FILSPARI sales, particularly due to early adoption in focal segmental glomerulosclerosis (FSGS) and continued growth in immunoglobulin A nephropathy (IgAN). The company generated $220.2 million in U.S. net product sales, with FILSPARI contributing $200.2 million, a 120% increase year-over-year. Travere also provided updates on its pipeline, including progress in studies for pegtibatinase and plans to initiate a Phase IV study for FSGS patients of African ancestry, while reiterating its target of over $3 billion in annual FILSPARI sales by 2033.
Travere Therapeutics Q3 2026 Earnings Call Transcript
Travere Therapeutics reported strong Q3 2026 financial results, with net product sales exceeding $200 million for the first time, primarily driven by FILSPARI for IgA nephropathy and FSGS. The company is confident in achieving over $3 billion in annual FILSPARI sales by 2033, supported by strong commercial execution, high patient adherence, and strategic advancements in its patent portfolio. Additionally, Travere Therapeutics is progressing its pipeline with pegtibatinase for classical HCU and Sivo rebrutinib for immune-mediated kidney diseases.
TVTX: FILSPARI growth lifted revenue, while major pipeline investment deepened losses
Travere Therapeutics (TVTX) reported a rise in Q3 revenue, driven by strong sales of FILSPARI. However, the company experienced deeper losses due to significant investment in its civorebrutinib IPR&D program and increased commercial and pipeline spending. While liquidity is sufficient for over 12 months, the company acknowledges ongoing risks related to execution, pricing, supply, and clinical trials.
Q3 revenue rises to $225M, but Travere Therapeutics (TVTX) swings to a loss.
Travere Therapeutics (TVTX) reported a net loss of $52.3 million in Q3 2026, a significant swing from a net income of $25.7 million in the prior year, despite a rise in total revenue to $224.6 million from $164.9 million. The loss was primarily driven by a $113.1 million in-process research and development expense related to the acquisition of civorebrutinib. FILSPARI sales significantly increased to $200.2 million, contributing to the overall revenue growth.
Travere Therapeutics, Inc. (TVTX) Seasonal returns chart
This article from Yahoo Finance focuses on Travere Therapeutics, Inc. (TVTX) and its historical seasonality. It presents a chart showing the average monthly price return for TVTX between 2016 and 2026. The article also provides current stock information, including the real-time price, recent performance, and details about an upcoming Q3 2026 earnings call.
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Corcept Therapeutics (CORT) and Incyte (INCY)
Three analysts have issued bullish sentiments on healthcare companies Travere Therapeutics (TVTX), Corcept Therapeutics (CORT), and Incyte (INCY). Joseph Pantginis of H.C. Wainwright reiterated a Buy rating for Travere Therapeutics with a $67.00 price target, while Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics with a $161.00 price target. John Newman, also from Canaccord Genuity, maintained a Buy rating on Incyte with a price target of $152.00.
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Therapeutics, Inc. (Nasdaq: TVTX) announced it will report its third quarter 2026 financial results on Monday, November 2, 2026, after the close of U.S. financial markets. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Information for accessing the webcast and dial-in details will be available on the Investor page of Travere’s website.
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Therapeutics, Inc. (Nasdaq: TVTX) announced it will report its third quarter 2026 financial results on Monday, November 2, 2026, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Information for accessing the webcast and dial-in details can be found on the Investor page of Travere's website.
Travere Therapeutics, Inc. Estimates – NASDAQ:TVTX
This article provides an overview of Travere Therapeutics, Inc. (NASDAQ:TVTX) financial data and analyst estimates on TradingView. It highlights sections for exploring financial actuals and estimates across various statements and valuation metrics. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.
TVTX Q3'26 Earnings: EPS estimate is (0.07) USD
Travere Therapeutics, Inc. (TVTX) is scheduled to announce its Q3'26 results on October 22, with earnings expected around 8:00 AM ET. The company's revenue estimate for the quarter is $195.94 million, and the estimated earnings per share (EPS) is ($0.07). This article provides a brief overview of past revenue and EPS performance alongside the current quarter's estimates.
The CEO exercises options at $8.93 and sells shares in Travere Therapeutics (TVTX).
Travere Therapeutics CEO Eric M. Dube exercised stock options on October 15, 2026, acquiring 43,735 shares at $26.88 and 200,000 shares at $8.93. Concurrently, he sold a total of 243,735 shares across three transactions at weighted average prices ranging from $52.9672 to $55.0179, under a Rule 10b5-1(c) plan adopted in June 2026. After these transactions, Dube holds 328,925 stock option contracts and 432,886 common stock shares directly.
Form 144 TRAVERE THERAPEUTICS For: 15 October By Investing.com
This article from Investing.com announces the filing of Form 144 for Travere Therapeutics (TVTX) on October 15. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal detail beyond this announcement, indicating it is likely a routine disclosure.
Form 144 TRAVERE THERAPEUTICS For: 15 October By Investing.com
This article from Investing.com reports on a Form 144 filing for Travere Therapeutics (TVTX) on October 15. The article presents the title of the filing along with the stock symbol and its current performance. Beyond the title and stock performance, no specific details about the content of the Form 144 filing are provided.
An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX).
Eric Dube, a director and officer at Travere Therapeutics (TVTX), has proposed selling 243,735 common shares, valued at approximately $12.98 million, with an approximate sale date of October 15, 2026. These shares are from the exercise of stock options. Additionally, the filing details three prior 10b5-1 sales by Dube in September 2026, totaling significant share amounts and values.
TVTX Q3'26 Earnings: revenue estimate is 195.68M USD
Travere Therapeutics, Inc. (TVTX) is scheduled to announce its Q3'26 earnings on October 22nd, with an estimated revenue of $195.68 million and an anticipated EPS of $0.03. The article provides a table detailing reported and estimated revenue and EPS, along with surprise percentages, for Q3'25 through Q3'26.
Learn Why The Bull Case For Travere Therapeutics Stock Could Change Following FILSPARI Kidney Data
Travere Therapeutics shared positive FILSPARI data at ASN Kidney Week 2026, including strong remission rates in IgA nephropathy and FSGS, which could significantly alter the investment outlook for the stock. This data reinforces the potential for FILSPARI as an early-line treatment and supports an expanded label, driving future revenue growth and potentially increasing the company's valuation. Investors are now considering how these clinical advancements could impact Travere's financial projections and market sentiment.
Learn Why The Bull Case For Travere Therapeutics Stock Could Change Following FILSPARI Kidney Data
Travere Therapeutics' FILSPARI drug presented positive data at ASN Kidney Week 2026, reinforcing its potential for IgA nephropathy and FSGS treatment. The data, including strong remission rates and stable kidney function, could support broader use and an expanded label for FILSPARI. While analysts have varying revenue forecasts, the positive clinical results may lead to a re-evaluation of Travere Therapeutics' investment potential and its current valuation.
Behavioral Patterns of TVTX and Institutional Flows
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) with AI-generated signals, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct trading strategies—position, momentum breakout, and risk hedging—along with key support and resistance levels across different time horizons. The analysis emphasizes a favorable risk-reward setup targeting an 18.2% gain against a 0.3% risk.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 12, 2026
Travere Therapeutics, Inc. announced inducement equity grants to 33 new employees on October 10, 2026, comprising 36,000 stock options and 142,580 restricted stock units. These grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment. The stock options have an exercise price of $52.02 and both options and RSUs vest over four years, subject to continued employment.
Travere Therapeutics (TVTX) Could Be 28% Undervalued As FILSPARI Data And Patent Land
Travere Therapeutics (TVTX) is considered 28% undervalued, with a fair value pegged at $74.14, despite recent stock price volatility. This optimism is driven by new positive FILSPARI data and patent protection extending to 2037, strengthening its rare kidney disease franchise. The company's improving financial health, including rapid product sales growth and reduced net losses, underpins the positive outlook, although regulatory setbacks or slow adoption of FILSPARI remain key risks.
Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?
Travere Therapeutics announced new positive data for FILSPARI at ASN Kidney Week 2026, reinforcing its efficacy and safety in IgA nephropathy and FSGS, and extending patent protection into 2037. This data could significantly impact the company's investment narrative, pricing power, and long-term planning, particularly given its reliance on FILSPARI. Analysts are forecasting substantial revenue and earnings growth by 2029, suggesting a potential upside for the stock.
Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?
Travere Therapeutics recently presented new FILSPARI data at ASN Kidney Week 2026, highlighting the drug's efficacy, renal protection, and safety in IgA nephropathy and FSGS, alongside real-world findings. The company also secured patent extensions for FILSPARI's use, strengthening its market position and pricing power. This new data and intellectual property protection are expected to influence Travere Therapeutics' investment outlook and physician perception of FILSPARI.
How (TVTX) Movements Inform Risk Allocation Models
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) using AI models, identifying weak near- and mid-term sentiment but a strong long-term outlook. It outlines three trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels to inform risk allocation decisions for TVTX.
Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's biopharmaceutical focus on rare kidney and metabolic diseases, highlighting its key products and clinical-stage programs. The article also presents performance metrics against the S&P 500 and earnings trends.
Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history
This article provides a comprehensive overview of Travere Therapeutics, Inc. (TVTX) stock, including its current price, historical data, and financial performance. It details the company's biopharmaceutical focus on rare kidney and metabolic diseases, highlighting key products like FILSPARI and clinical-stage programs. The report also includes analyst insights, earnings trends, and valuation measures.
Travere Therapeutics (TVTX) to Present New FILSPARI Data at ASN Kidney Week 2026
Travere Therapeutics (TVTX) is set to present nine new studies on its drug FILSPARI at ASN Kidney Week 2026, highlighting promising results for treating IgA nephropathy and FSGS. Despite positive clinical data, the company's stock trades at a high Price-to-Sales ratio of 9.16, indicating significant market expectations for future growth, while it remains unprofitable with weak financial strength. Insider selling activity suggests caution, although six gurus hold shares.
Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into the officers and directors of Travere Therapeutics for potential breaches of fiduciary duties through self-dealing. This probe aims to uncover possible harm to shareholders and may lead to legal damages and governance reforms. Long-term investors are urged to contact the law firm to protect their rights and address concerns regarding corporate governance.
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Kuehn Law is investigating whether officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties due to potential self-dealing. The firm encourages long-term TVTX stockholders to contact them to explore potential damages and corporate governance reforms. The consultation and case are free, with the law firm covering all costs.
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Kuehn Law is encouraging investors of Travere Therapeutics, Inc. (TVTX) to contact their law firm. This announcement from PR Newswire contains only a headline and no further details regarding the nature of the encouragement or potential legal actions.
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?
Travere Therapeutics (TVTX) recently secured a patent extension for its drug FILSPARI, now protected until October 2037 for focal segmental glomerulosclerosis. Despite mixed short-term stock performance, the company shows strong long-term sentiment and is considered 19% undervalued by many, with a fair value pegged at $74.14. However, a different valuation perspective, using sales multiples, suggests the stock might be richly priced compared to peers, indicating less room for error if the FILSPARI thesis faces challenges.
Travere Therapeutics Inc. (TVTX) Key Financial Ratios – Valuation, Profitability & More
This article provides a detailed analysis of Travere Therapeutics Inc. (TVTX) through its key financial ratios across valuation, profitability, growth, solvency, and operating efficiency. It presents both quarterly and annual data, including comparisons against peer medians for various metrics. The report highlights the company's performance in revenue, EBIT, net profit, and EPS growth, alongside solvency and efficiency ratios for investors.